ヒト用ワクチンアジュバントの市場規模および予測、世界および地域別シェア、動向、成長機会分析レポート対象範囲：タイプ別、用途別、エンドユーザー別、地域別

ヒト用ワクチンアジュバントの世界市場は、2022年の15億7,100万米ドルから2030年には44億8,900万米ドルに達すると予測されます。2022年から2030年までのCAGRは14.0%で成長すると推定されます。ヒト用ワクチンアジュバント市場の成長を促進する主な要因としては、慢性疾患の有病率の上昇、予防接種プログラムへの注目の高まりなどが挙げられます。

ヒト用ワクチンアジュバント市場の市場機会

アジュバントはワクチンの有効性と安全性を向上させるため、製薬業界の拡大がアジュバント需要にプラスの影響を与えると予想されます。製薬業界では、感染症、がん、自己免疫疾患への関心が高まっており、これらの特定の疾患領域をターゲットとした個別化ワクチンやアジュバントを開発するための基盤が提供されています。このことは、アジュバントメーカーにとって、これらの疾患のワクチンに対する免疫反応を高めるための特殊なアジュバントを開発する機会となります。

米国は世界で最も研究開発集約型の製薬産業のひとつです。欧州製薬団体連合会（EFPIA）によると、北米市場（米国とカナダ）のシェアは49.1%で、欧州、中国、日本を大きく引き離して世界最大の市場を維持しています。米国は革新的な研究開発投資の世界的リーダーであり、過去10年間に世界の新分子の半分以上を生産しました。さらに、EFPIAによれば、2021年には世界の医薬品売上高の49.1％を北米が占めるのに対し、欧州は23.4％です。

同様に、EFPIAによると、2016年から2021年の間にブラジル、中国、インドの製薬業界はそれぞれ11.7%、6.7%、11.8%成長し、上位5つのEU市場と米国市場はそれぞれ平均5.8%、5.6%の市場成長を記録しました。さらに、インド・ブランド・エクイティ財団（IBEF）によれば、インドは世界の製薬業界の主要な新興国です。同国は世界最大のジェネリック医薬品貿易国であり、世界全体の供給量の20％近くを占めています。また、世界の予防接種需要の50％を供給しています。国内の製薬業界には、3,000の製薬会社と～10,500の製造ユニットのネットワークがあります。インド政府の公式発表によると、インドの製薬セクターの市場規模は約500億米ドルであり、そのうち250億米ドル以上が輸出によるものです。インドは世界のジェネリック医薬品輸出の約20％を占めています。さらに、日本は世界最大の医薬品市場のひとつです。厚生労働省の「医薬品生産動態統計」によると、2020年の日本の医療用・非医療用医薬品市場は1,070億米ドルでした。

業界が進化と革新を続ける中、個別化ワクチンの開発をサポートできるアジュバントへの需要が高まっており、ヒト用ワクチンアジュバント市場の大幅な成長と投資の原動力となっています。このように、世界の製薬産業の成長は、今後数年間、ヒト用ワクチンアジュバント市場に有利な成長機会をもたらす可能性が高いです。

ヒト用ワクチンアジュバント市場を阻害する要因

ヒト用ワクチンアジュバントの製造は、厳しい規制要件と品質管理対策を伴う複雑なプロセスです。アジュバントの製造には、最終製品の純度、安全性、有効性を確保するため、適正製造基準（GMP）やその他の規制基準を厳格に遵守した特殊な設備や施設が必要です。こうした要件を満たすための資源や専門知識が限られているため、メーカー、特に中小企業や新規参入企業にとっては大きな課題となりうる。

規制上の課題もまた、ヒト用ワクチンアジュバント市場の抑制に大きな役割を果たしています。アジュバントはワクチンの重要な成分と考えられており、欧州の欧州医薬品庁（EMA）や米国の食品医薬品局（FDA）などの保健当局による厳しい規制監督を受けています。アジュバントの規制当局による承認プロセスは、安全性、有効性、品質を実証するための広範な前臨床および臨床データを必要とするため、長く複雑なものとなります。規制当局の承認を得るために必要なコストと時間は相当なものになるため、メーカーにとっては大きな障壁となりうる。このように、上記の要因がヒト用ワクチンアジュバント市場の成長を妨げています。

ヒト用ワクチンアジュバント市場セグメント別概要

ヒト用ワクチンアジュバント市場は、タイプ別に粒子状アジュバント、乳剤アジュバント、配合アジュバント、その他に区分されます。粒子状アジュバントセグメントが2022年の市場で大きなシェアを占めています。しかし、エマルジョンアジュバントセグメントは、2022年から2030年にかけて市場でより高いCAGRを記録すると予想されます。粒子状アジュバントは、多くの場合ナノメートルまたはマイクロメートルサイズの粒子で構成され、病原体や細胞構造を模倣して強固な免疫反応を刺激するように設計されています。これらのアジュバントは、免疫細胞による抗原の取り込みを促進し、免疫活性化を促進します。粒子状アジュバントの顕著な例としては、アルミニウム塩（ミョウバン）が挙げられ、これらは抗体反応を増強するためにヒト用ワクチンに数十年にわたって使用されてきたほか、ウイルス様粒子（VLP）やナノ粒子ベースのアジュバントなどの新しい開発も行われています。

ヒト用ワクチンアジュバント市場は、用途別にインフルエンザ、肝炎、ヒトパピローマウイルス（HPV）、その他に区分されます。インフルエンザ分野は2022年に市場で最大のシェアを占め、2022年から2030年にかけて市場で最も高いCAGRを記録すると予想されています。インフルエンザワクチンは、季節性インフルエンザの流行やパンデミックの可能性を予防するために極めて重要です。インフルエンザワクチンは、急速に進化するウイルスを対象としているため、流行株に合わせて継続的にワクチンを更新する必要があります。インフルエンザワクチンに使用されるアジュバントは、特に高齢者や免疫不全者などのハイリスク集団における免疫反応を増強します。アジュバントはまた、広く防御的な交差反応性免疫応答の発現をサポートします。

エンドユーザー別では、ヒト用ワクチンアジュバント市場は製薬・バイオテクノロジー企業、CMO・CRO、その他に区分されます。製薬・バイオテクノロジー企業セグメントは2022年に市場で最大のシェアを占め、2022年から2030年にかけて市場で最も高いCAGRを記録すると予想されています。製薬・バイオテクノロジー企業は、多様な感染症や健康状態をターゲットとしたアジュバントワクチン製剤を含むワクチンの研究、開発、商業化において中心的な役割を果たしています。これらの企業はワクチン革新の最前線に立ち、前臨床および臨床開発段階を通じてアジュバント技術、ワクチン候補、アジュバント添加ワクチン製剤の発見と最適化を推進しています。

ヒト用ワクチンアジュバント市場地域別概要

2022年のヒト用ワクチンアジュバントの世界市場シェアは北米が最大でした。北米のヒト用ワクチンアジュバント市場では米国が大きなシェアを占めています。この国の市場成長は主に、ヘルスケアに対する政府支出の増加と、感染症をより効率的に治療するための新規ワクチン製剤に対する需要の急増によるものです。米国メディケア＆メディケイドサービスセンターによると、米国の国民医療費は2021年に2.7％増加し、4兆3,000億米ドル、1人当たり1万2,914米ドルに達しました。医療費は国内総生産（GDP）の18.3％を占める。米国保健社会福祉省の発表によると、2019年から2028年にかけて国民医療費は年率5.4％で成長し、2028年には6兆2,000億米ドルに達すると予想されています。医療支出の増加は、ワクチンの研究開発への資金配分の増加につながり、ヒト用ワクチンアジュバントの需要を煽る可能性があります。

2020年7月に発表されたGlobal Burden of Disease研究から得られた新たな知見によると、米国では非伝染性疾患と感染症の負担が大きく増加しています。ジョンズ・ホプキンス大学によると、SARS、ライム病、デング熱、ウエストナイルウイルス、ジカウイルス感染症などの症例が、米国では過去20年間に急増しています。また、マラリア、結核、コレラ、百日咳、インフルエンザ、肺炎球菌感染症、淋病などの再興疾患の発生率も増加しています。同様に、米国疾病対策予防センター（CDC）によると、インフルエンザは2010年から2022年の間に、年間10万人から71万人の入院と4900人から5万2000人の死亡をもたらしました。2023年のHPVとがんに関するICO/IARC情報センターの報告によると、米国にはHPVに関連した子宮頸がんを発症するリスクのある15歳以上の女性が1億4,050万人います。米国では、一般人口の女性の3.9％近くが、ある時点で子宮頸部HPV16/18感染を保有していると予測され、浸潤性子宮頸がんの71.2％がHPV16または18に起因しています。このように、さまざまな感染症や再興疾患の発生率の増加は、企業のワクチン開発への取り組みを後押しし、米国におけるヒト用ワクチンアジュバント市場の成長に拍車をかけています。

米国政府は、国内で医薬品やヘルスケア製品を開発・商業化するための環境整備に努めています。米国には、ファイザー、ノバルティス、ボストン・サイエンティフィック、インテグラ・ライフサイエンシズ、アムジェン、アボットなど、医薬品・医療機器市場の潜在的プレーヤーが複数存在し、医薬品・医療機器業界のイノベーションに関するさまざまな特許を取得しています。このように、様々な製薬大手による医薬品開発活動の増加は、米国のヒト用ワクチンアジュバント市場を強化しています。

ヒト用ワクチンアジュバント市場に関する報告書を作成する際に参照した主な一次情報および二次情報には、世界銀行データ、国民保健サービス（NHS）、FDA（食品医薬品局）、EMA（欧州医薬品庁）、WHO（世界保健機関）などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

• 主要な洞察

第3章 調査手法

• 調査範囲
• 2次調査
• 1次調査

第4章 ヒト用ワクチンアジュバントの市場情勢

• PEST分析

第5章 ヒト用ワクチンアジュバント市場：主要市場力学

• ヒト用ワクチンアジュバント市場：主要市場力学
• 市場促進要因
  • 慢性疾患の増加
  • 予防接種プログラムへの注目の高まり
• 市場抑制要因
  • 製造の複雑さと規制上の課題
• 市場機会
  • 製薬業界の成長
• 今後の動向
  • 個別化ワクチンの動向の高まり
• 促進要因と抑制要因の影響

第6章 ヒト用ワクチンアジュバント市場：世界市場分析

• ヒト用ワクチンアジュバントの市場収益、2022年～2030年
• ヒト用ワクチンアジュバントの市場予測分析

第7章 ヒト用ワクチンアジュバントの市場分析：タイプ別

• 粒子状アジュバント
• エマルジョンアジュバント
• 配合アジュバント
• その他

第8章 ヒト用ワクチンアジュバントの市場分析：用途別

• インフルエンザ
• 肝炎
• ヒト乳頭腫ウイルス（HPV）
• その他

第9章 ヒト用ワクチンアジュバントの市場分析：エンドユーザー別

• 製薬企業およびバイオテクノロジー企業
• CMOおよびCRO
• その他

第10章 ヒト用ワクチンアジュバント市場：地域別分析

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • APACのその他諸国
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • アラブ首長国連邦
  • その他中東とアフリカ
• 中南米
  • ブラジル
  • アルゼンチン
  • その他中南米

第11章 業界情勢

第12章 企業プロファイル

• Novartis AG
• Dynavax Technologies Corp
• CSL Ltd
• Seppic SA
• SPI Pharma Inc
• Hawaii Biotech Inc
• Croda International Plc
• Novavax Inc
• Phibro Animal Health Corp
• Creative Biolabs Inc

第13章 企業プロファイル付録

List Of Tables

• Table 1. Human Vaccine Adjuvants Market Segmentation
• Table 2. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Table 3. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
• Table 4. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
• Table 5. Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
• Table 6. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 7. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 8. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 9. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
• Table 10. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 11. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 12. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 13. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 14. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 15. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 16. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 17. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 18. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 19. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 20. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 21. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 22. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
• Table 23. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 24. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 25. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 26. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 27. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 28. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 29. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 30. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 31. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 32. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 33. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 34. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 35. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 36. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 37. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 38. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 39. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 40. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 41. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 42. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 43. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 44. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
• Table 45. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 46. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 47. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 48. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 49. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 50. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 51. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 52. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 53. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 54. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 55. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 56. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 57. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 58. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 59. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 60. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 61. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 62. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 63. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 64. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 65. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 66. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
• Table 67. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 68. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 69. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 70. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 71. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 72. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 73. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 74. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 75. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 76. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 77. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 78. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 79. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 80. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 81. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 82. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Country
• Table 83. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 84. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 85. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 86. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
• Table 87. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 88. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
• Table 89. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
• Table 90. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
• Table 91. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
• Table 92. Recent Growth Strategies in the Human Vaccine Adjuvants Market
• Table 93. Glossary of Terms, Global Human Vaccine Adjuvants Market

List Of Figures

• Figure 1. Human Vaccine Adjuvants Market Segmentation, by Geography
• Figure 2. PEST Analysis
• Figure 3. Impact Analysis of Drivers and Restraints
• Figure 4. Human Vaccine Adjuvants Market Breakdown by Geography, 2022 and 2030 (%)
• Figure 5. Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
• Figure 6. Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
• Figure 7. Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 8. Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 9. Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 10. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 11. Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
• Figure 12. Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 13. Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 14. Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 15. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 16. Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
• Figure 17. Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 18. CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 19. Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 20. Human Vaccine Adjuvants Market Breakdown by Region, 2022 and 2030 (%)
• Figure 21. North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 22. North America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
• Figure 23. North America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
• Figure 24. North America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
• Figure 25. North America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
• Figure 26. United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 27. Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 28. Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 29. Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 30. Europe: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
• Figure 31. Europe: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
• Figure 32. Europe: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
• Figure 33. Europe: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
• Figure 34. Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 35. United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 36. France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 37. Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 38. Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 39. Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 40. Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 41. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
• Figure 42. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
• Figure 43. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
• Figure 44. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
• Figure 45. China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 46. Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 47. India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 48. Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 49. South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 50. Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 51. Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 52. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
• Figure 53. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
• Figure 54. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
• Figure 55. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
• Figure 56. Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 57. South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 58. United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 59. Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 60. South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 61. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
• Figure 62. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
• Figure 63. South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
• Figure 64. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
• Figure 65. Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 66. Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
• Figure 67. Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

The global human vaccine adjuvants market is expected to reach US$ 4.489 billion in 2030 from US$ 1.571 billion in 2022. The market is estimated to grow with a CAGR of 14.0% from 2022 to 2030. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and growing focus on immunization programs.

Market Opportunities of Human Vaccine Adjuvants Market

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases.

The US has one of the most R&D-intensive pharmaceutical industries globally. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the North America market (US and Canada) remained the world's largest market with a 49.1% share, well ahead of Europe, China, and Japan. The US is the global leader in innovative R&D investments, and the country produced over half of the world's new molecules in the last decade. Additionally, as per EFPIA, in 2021, North America accounted for 49.1% of global pharmaceutical sales, compared with 23.4% for Europe.

Similarly, according to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.

As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the human vaccine adjuvants market in the coming years.

Factors Hampering Human Vaccine Adjuvants Market

Manufacturing human vaccine adjuvant is a complex process involving stringent regulatory requirements and quality control measures. The production of adjuvants requires specialized equipment and facilities with strict adherence to Good Manufacturing Practices (GMP) and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements.

Regulatory challenges also play a significant role in restraining the human vaccine adjuvants market. Adjuvants are considered critical components of vaccines, and they are subjected to strict regulatory oversight by health authorities such as the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the US. The regulatory approval process for adjuvants can be lengthy and complex, requiring extensive preclinical and clinical data to demonstrate safety, efficacy, and quality. It can pose a significant barrier for manufacturers, as the cost and time required to obtain regulatory approval can be substantial. Thus, the factors mentioned above hamper the growth of the human vaccine adjuvants market.

Human Vaccine Adjuvants Market: Segmental Overview

Based on type, the human vaccine adjuvants market is segmented into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants.

By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.

In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.

Human Vaccine Adjuvants Market: Geographical Overview

North America accounted for the largest global human vaccine adjuvants market share in 2022. The US holds a significant share of North America's human vaccine adjuvants market. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants.

According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the human vaccine adjuvants market growth in the US.

The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the human vaccine adjuvants market in the US.

A few of the major primary and secondary sources referred to while preparing the report on the human vaccine adjuvants market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the human vaccine adjuvants market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.  
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the human vaccine adjuvants market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Human Vaccine Adjuvants Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis

5. Human Vaccine Adjuvants Market - Key Market Dynamics

• 5.1 Human Vaccine Adjuvants Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Rising Prevalence of Chronic Diseases
  • 5.2.2 Growing Focus on Immunization Programs
• 5.3 Market Restraints
  • 5.3.1 Manufacturing Complexities and Regulatory Challenges
• 5.4 Market Opportunities
  • 5.4.1 Growing Pharmaceutical Industry
• 5.5 Future Trends
  • 5.5.1 Rising Trend of Personalized Vaccines
• 5.6 Impact of Drivers and Restraints:

6. Human Vaccine Adjuvants Market - Global Market Analysis

• 6.1 Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
• 6.2 Human Vaccine Adjuvants Market Forecast Analysis

7. Human Vaccine Adjuvants Market Analysis - by Type

• 7.1 Particulate Adjuvant
  • 7.1.1 Overview
  • 7.1.2 Particulate Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 7.2 Emulsion Adjuvant
  • 7.2.1 Overview
  • 7.2.2 Emulsion Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 7.3 Combination Adjuvant
  • 7.3.1 Overview
  • 7.3.2 Combination Adjuvant: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Others
  • 7.4.1 Overview
  • 7.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Human Vaccine Adjuvants Market Analysis - by Application

• 8.1 Influenza
  • 8.1.1 Overview
  • 8.1.2 Influenza: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 8.2 Hepatitis
  • 8.2.1 Overview
  • 8.2.2 Hepatitis: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 8.3 Human papilloma virus (HPV)
  • 8.3.1 Overview
  • 8.3.2 Human papilloma virus (HPV): Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Others
  • 8.4.1 Overview
  • 8.4.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Human Vaccine Adjuvants Market Analysis - by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Overview
  • 9.1.2 Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 9.2 CMOs and CROs
  • 9.2.1 Overview
  • 9.2.2 CMOs and CROs: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 9.3 Others
  • 9.3.1 Overview
  • 9.3.2 Others: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

10. Human Vaccine Adjuvants Market - Geographical Analysis

• 10.1 Overview
• 10.2 North America
  • 10.2.1 North America Human Vaccine Adjuvants Market Overview
  • 10.2.2 North America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.2.3 North America: Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.2.3.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
  • 10.2.4 North America: Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.2.4.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
  • 10.2.5 North America: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.2.5.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
  • 10.2.6 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.2.6.1 North America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.2.6.2 United States: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.2.6.2.1 United States: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.2.6.2.2 United States: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.2.6.2.3 United States: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.2.6.3 Canada: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.2.6.3.1 Canada: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.2.6.3.2 Canada: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.2.6.3.3 Canada: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.2.6.4 Mexico: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.2.6.4.1 Mexico: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.2.6.4.2 Mexico: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.2.6.4.3 Mexico: Human Vaccine Adjuvants Market Breakdown, by End User
• 10.3 Europe
  • 10.3.1 Europe Human Vaccine Adjuvants Market Overview
  • 10.3.2 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3.3 Europe: Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.3.3.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
  • 10.3.4 Europe: Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.3.4.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
  • 10.3.5 Europe: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.3.5.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
  • 10.3.6 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.3.6.1 Europe: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.3.6.2 Germany: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.3.6.2.1 Germany: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.6.2.2 Germany: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.6.2.3 Germany: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.3.6.3 United Kingdom: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.3.6.3.1 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.6.3.2 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.6.3.3 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.3.6.4 France: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.3.6.4.1 France: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.6.4.2 France: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.6.4.3 France: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.3.6.5 Italy: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.3.6.5.1 Italy: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.6.5.2 Italy: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.6.5.3 Italy: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.3.6.6 Spain: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.3.6.6.1 Spain: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.6.6.2 Spain: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.6.6.3 Spain: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.3.6.7 Rest of Europe: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.3.6.7.1 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.3.6.7.2 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.3.6.7.3 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by End User
• 10.4 Asia Pacific
  • 10.4.1 Asia Pacific Human Vaccine Adjuvants Market Overview
  • 10.4.2 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.4.3 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.4.3.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
  • 10.4.4 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.4.4.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
  • 10.4.5 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.4.5.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
  • 10.4.6 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.4.6.1 Asia Pacific: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.4.6.2 China: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.4.6.2.1 China: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.6.2.2 China: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.6.2.3 China: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.4.6.3 Japan: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.4.6.3.1 Japan: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.6.3.2 Japan: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.6.3.3 Japan: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.4.6.4 India: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.4.6.4.1 India: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.6.4.2 India: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.6.4.3 India: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.4.6.5 Australia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.4.6.5.1 Australia: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.6.5.2 Australia: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.6.5.3 Australia: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.4.6.6 South Korea: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.4.6.6.1 South Korea: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.6.6.2 South Korea: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.6.6.3 South Korea: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.4.6.7 Rest of APAC: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.4.6.7.1 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.4.6.7.2 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.4.6.7.3 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by End User
• 10.5 Middle East and Africa
  • 10.5.1 Middle East and Africa Human Vaccine Adjuvants Market Overview
  • 10.5.2 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.5.3 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.5.3.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
  • 10.5.4 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.5.4.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
  • 10.5.5 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.5.5.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
  • 10.5.6 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.5.6.1 Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.5.6.2 Saudi Arabia: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.5.6.2.1 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.5.6.2.2 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.5.6.2.3 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.5.6.3 South Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.5.6.3.1 South Africa: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.5.6.3.2 South Africa: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.5.6.3.3 South Africa: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.5.6.4 United Arab Emirates: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.5.6.4.1 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.5.6.4.2 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.5.6.4.3 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.5.6.5 Rest of Middle East and Africa: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.5.6.5.1 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.5.6.5.2 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.5.6.5.3 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
• 10.6 South and Central America
  • 10.6.1 South and Central America Human Vaccine Adjuvants Market Overview
  • 10.6.2 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 | (US$ Million)
  • 10.6.3 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
    • 10.6.3.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
  • 10.6.4 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
    • 10.6.4.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Application
  • 10.6.5 South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.6.5.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by End User
  • 10.6.6 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.6.6.1 South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
    • 10.6.6.2 Brazil: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.6.6.2.1 Brazil: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.6.6.2.2 Brazil: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.6.6.2.3 Brazil: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.6.6.3 Argentina: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.6.6.3.1 Argentina: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.6.6.3.2 Argentina: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.6.6.3.3 Argentina: Human Vaccine Adjuvants Market Breakdown, by End User
    • 10.6.6.4 Rest of South and Central America: Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.6.6.4.1 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
      • 10.6.6.4.2 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
      • 10.6.6.4.3 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User

11. Industry Landscape

• 11.1 Overview

12. Company Profiles

• 12.1 Novartis AG
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Dynavax Technologies Corp
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 CSL Ltd
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Seppic SA
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 SPI Pharma Inc
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Hawaii Biotech Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Croda International Plc
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 Novavax Inc
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 Phibro Animal Health Corp
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments
• 12.10 Creative Biolabs Inc
  • 12.10.1 Key Facts
  • 12.10.2 Business Description
  • 12.10.3 Products and Services
  • 12.10.4 Financial Overview
  • 12.10.5 SWOT Analysis
  • 12.10.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms